With renal mass detection on the rise,
FIND a Brighter Path Ahead
Breakthrough imaging could transform diagnosis of clear cell renal cell carcinoma1
With renal mass detection on the rise,
Find a Brighter Path Ahead
Breakthrough imaging could transform diagnosis of clear cell renal cell carcinoma1
Increased renal mass detection presents numerous diagnostic challenges—especially in masses <4 cm.2 Novel diagnostic technology in clear cell renal cell carcinoma (ccRCC) is critical for optimizing patient care.3
References: 1. FDA accepts BLA for TLX250-CDx (Zircaix®) for kidney cancer imaging, grants priority review. News release. Telix Pharmaceuticals. February 26, 2025. Accessed October 27, 2025. https://telixpharma.com/news-views/fda-accepts-bla-for-tlx250-cdx-zircaix-for-kidney-cancer-imaging-grants-priority-review/ 2. Yanagi M, Kiriyama T, Akatsuka J, et al. Differential diagnosis and prognosis of small renal masses: association with collateral vessels detected using contrast-enhanced computed tomography. BMC Cancer. 2022;22(1):856. 3. Li C, Hu Q, Liang SH. CAIX-targeted PET imaging agents based on acetazolamide small molecule for clear cell renal cell carcinoma. Am J Nucl Med Mol Imaging. 2025;15(1):37-43. 4. Skelton WP, Leslie SW, Guzman N. Renal Mass. In: StatPearls. Treasure Island (FL): StatPearls Publishing; April 12, 2025. 5. van Oostenbrugge TJ, Fütterer JJ, Mulders PFA. Diagnostic imaging for solid renal tumors: a pictorial review. Kidney Cancer. 2018;2(2):79-93.